| Characteristics and outcomes of adults with cytomegalovirus‐associated thrombocytopenia: a case series and literature review T Shragai, E Lebel, D Deshet, D Varon, I Avivi, I Kirgner, N Sarid British Journal of Haematology 191 (5), 863-867, 2020 | 22 | 2020 |
| Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: Results from a phase I clinical trial N Asherie, S Kfir-Erenfeld, B Avni, M Assayag, T Dubnikov, N Zalcman, ... Haematologica 108 (7), 1827, 2023 | 18 | 2023 |
| Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis S Kfir-Erenfeld, N Asherie, S Grisariu, B Avni, E Zimran, M Assayag, ... Clinical Cancer Research 28 (23), 5156-5166, 2022 | 18 | 2022 |
| Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma S Sheikh, E Lebel, S Trudel Future Oncology 16 (34), 2783-2798, 2020 | 17 | 2020 |
| Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study C Perry, S Ben Barouch, N Goldschmidt, N Sarid, Y Herishanu, L Shvidel, ... American journal of hematology 94 (9), 992-1001, 2019 | 17 | 2019 |
| Post-eculizumab meningococcaemia in vaccinated patients E Lebel, U Trahtemberg, C Block, O Zelig, H Elinav Clinical Microbiology and Infection 24 (1), 89-90, 2018 | 15 | 2018 |
| CD24 is a prognostic marker for multiple myeloma progression and survival N Gross Even-Zohar, M Pick, L Hofstetter, A Shaulov, B Nachmias, ... Journal of Clinical Medicine 11 (10), 2913, 2022 | 12 | 2022 |
| Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions E Lebel, D Ben-Yehuda, E Bohbot, Z Dranitzki, M Shalit, Y Tal The Journal of Allergy and Clinical Immunology: In Practice 4 (5), 1000-1002, 2016 | 12 | 2016 |
| Euthyroid submedian free T4 and subclinical hypothyroidism may have a detrimental clinical effect in Down syndrome A Tenenbaum, E Lebel, S Malkiel, Y Kastiel, A Abulibdeh, DH Zangen Hormone Research in Paediatrics 78 (2), 113-118, 2012 | 11 | 2012 |
| Romidepsin-bendamustine combination for relapsed/refractory T cell lymphoma B Nachmias, A Shaulov, D Lavie, N Goldschmidt, A Gural, R Saban, ... Acta Haematologica 141 (4), 216-221, 2019 | 10 | 2019 |
| Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg? V Vainstein, B Avni, S Grisariu, S Kfir-Erenfeld, N Asherie, B Nachmias, ... Cancers 15 (13), 3471, 2023 | 9 | 2023 |
| Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma E Lebel, B Nachmias, M Pick, N Gross Even-Zohar, ME Gatt Journal of Clinical Medicine 11 (7), 1809, 2022 | 9 | 2022 |
| Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART)(HBI0101) for the treatment of relapsed and refractory AL amyloidosis E Lebel, S Kfir-Erenfeld, N Asherie, S Grisariu, B Avni, S Elias, M Assayag, ... Blood 142, 538, 2023 | 8 | 2023 |
| Venetoclax in relapse/refractory AL amyloidosis—a multicenter international retrospective real-world study E Lebel, E Kastritis, G Palladini, P Milani, F Theodorakakou, S Aumann, ... Cancers 15 (6), 1710, 2023 | 8 | 2023 |
| Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma T Dubnikov Sharon, M Assayag, B Avni, S Kfir‐Erenfeld, E Lebel, ME Gatt, ... British Journal of Haematology 202 (1), 74-85, 2023 | 6 | 2023 |
| A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma O Bairey, A Taliansky, A Glik, A Amiel, S Yust‐Katz, R Gurion, M Zektser, ... Cancer 129 (24), 3905-3914, 2023 | 4 | 2023 |
| Supermobilizers with high CD34+ cell collection for autologous transplant and impact on survival outcomes in multiple myeloma E Lebel, K Lajkosz, E Masih-Khan, DE Reece, S Trudel, RE Tiedemann, ... Blood 138, 1837, 2021 | 4 | 2021 |
| Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma E Lebel, N Goldschmidt, T Siegal, A Lossos, S Rosenberg, C Makranz, ... Leukemia & Lymphoma 63 (9), 2102-2108, 2022 | 3 | 2022 |
| Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma S Gazal, E Lebel, Y Kalish, C Makranz, ME Gatt, N Goldschmidt, ... Oncology Research and Treatment 44 (1-2), 52-57, 2021 | 3 | 2021 |
| Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study E Luttwak, ME Gatt, E Lebel, N Lavi, T Tadmor, K Natalia, N Benyamini, ... Clinical Lymphoma Myeloma and Leukemia 20 (11), e850-e857, 2020 | 3 | 2020 |
